{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:24:33Z","timestamp":1786987473651,"version":"build-2736575974"},"reference-count":115,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.cpcardiol.2022.101366","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T21:48:07Z","timestamp":1660945687000},"page":"101366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["A Review of Cardiac Amyloidosis: Presentation, Diagnosis, and Treatment"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6404-1213","authenticated-orcid":false,"given":"Issa","family":"Pour-Ghaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandbir","family":"Bath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharif","family":"Kayali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deya","family":"Alkhatib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraja","family":"Yedlapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Rhea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami N.","family":"Khouzam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Jefferies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mannu","family":"Nayyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2022.101366_bib0001","doi-asserted-by":"crossref","first-page":"s30","DOI":"10.7861\/clinmedicine.18-2-s30","article-title":"Cardiac amyloidosis","volume":"18","author":"Martinez-Naharro","year":"2018","journal-title":"Clinical Medicine"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0002","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11912-017-0607-4","article-title":"Cardiac Amyloidosis: Diagnosis and Treatment Strategies","volume":"19","author":"Tuzovic","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0004","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (Light-Chain) Cardiac Amyloidosis A Review of Diagnosis and Therapy","volume":"68","author":"Falk","year":"2016","journal-title":"Journal of American College of Cardiology"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11886-019-1230-9","article-title":"Amyloid and the Heart","volume":"21","author":"Wolfson","year":"2019","journal-title":"Current Cardiology Reports"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-7-54","volume":"7","author":"Desport","year":"2012","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0008","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.rdc.2013.02.012","article-title":"Amyloidosis: A Clinical Overview","volume":"39","author":"Hazenberg","year":"2013","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0009","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11897-019-00446-x","article-title":"Amyloidosis in Heart Failure","volume":"16","author":"Ihne","year":"2019","journal-title":"Current Heart Failure Reports"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","article-title":"Cardiac amyloidosis: pathology, nomenclature, and typing","volume":"24","author":"Maleszewski","year":"2015","journal-title":"Cardiovascular Pathology"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0011","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/heartjnl-2016-310704","article-title":"Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response","volume":"103","author":"Grogan","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0012","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","article-title":"Transthyretin (TTR) Cardiac Amyloidosis","volume":"126","author":"Ruberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0013","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10741-019-09776-3","article-title":"Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement","volume":"24","author":"Rigopoulos","year":"2019","journal-title":"Heart Failure Reviews"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0014","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ehf2.12518","article-title":"Transthyretin cardiac amyloidosis: an update on diagnosis and treatment","volume":"6","author":"Yamamoto","year":"2019","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12471-019-1299-1","article-title":"Cardiac amyloidosis: the need for early diagnosis","volume":"27","author":"Oerlemans","year":"2019","journal-title":"Neth Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0016","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jacc.2018.01.016","article-title":"Spectrum of Restrictive and Infiltrative Cardiomyopathies Part 1 of a 2-Part Series","volume":"71","author":"Pereira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0017","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3233\/JND-180371","article-title":"Clinical Presentation, Diagnosis and Treatment of TTR Amyloidosis","volume":"6","author":"Kapoor","year":"2019","journal-title":"Journal of Neuromuscular Diseases"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0018","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/ane.13035","article-title":"Hereditary transthyretin-related amyloidosis","volume":"139","author":"Finsterer","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0019","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonzalez-Lopez","year":"2017","journal-title":"European Heart Journal"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0020","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association Between Ruptured Distal Biceps Tendon and Wild-Type Transthyretin Cardiac Amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0021","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","article-title":"Light Chain (AL) Amyloidosis: The Journey to Diagnosis","volume":"11","author":"McCausland","year":"2018","journal-title":"Patient"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0022","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/ndt\/gfy291","article-title":"AL amyloidosis: advances in diagnostics and treatment","volume":"34","author":"Rysava","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0023","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1042\/CS20160413","article-title":"Transthyretin amyloidosis: an under-recognized neuropathy and cardiomyopathy","volume":"131","author":"Galant","year":"2017","journal-title":"Clinical Science"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0024","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","article-title":"Treatment of cardiac transthyretin amyloidosis: an update","volume":"40","author":"Emdin","year":"2019","journal-title":"European Heart Journal"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0025","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1080\/00015385.2017.1335034","article-title":"Cardiac amyloidosis: pathogenesis, clinical context, diagnosis and management options","volume":"72","author":"Alkhawam","year":"2017","journal-title":"Acta Cardiologica"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-018-0952-8","article-title":"Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers","volume":"18","author":"Kyriakou","year":"2018","journal-title":"BMC Cardiovascular Disorders"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0027","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/aps.2018.38","article-title":"Current and future circulating biomarkers for cardiac amyloidosis","volume":"39","author":"Luciani","year":"2018","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0028","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0029","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14779072.2019.1662723","article-title":"Amyloid transthyretin cardiac amyloidosis: diagnosis and management","volume":"17","author":"Di Giovanni","year":"2019","journal-title":"Expert Review of Cardiovascular Therapy"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CRD.0b013e3181bdba8f","article-title":"Cardiac Amyloidosis Approaches to Diagnosis and Management","volume":"18","author":"Desai","year":"2010","journal-title":"Cardiology in Review"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0031","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/13506129.2015.1037831","article-title":"Can echocardiography and ECG discriminate hereditary transthyretin V30M amyloidosis from hypertrophic cardiomyopathy?","volume":"22","author":"Gustavsson","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0032","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/S0002-8703(97)70017-6","article-title":"Signal-averaged electrocardiography in patients with AL (primary) amyloidosis","volume":"134","author":"Dubrey","year":"1997","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0033","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","article-title":"The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement","volume":"91","author":"Dubrey","year":"1998","journal-title":"Q J Med"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0034","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1540-8175.1991.tb01395.x","article-title":"Two-dimensional echocardiography in myocardial amyloidosis","volume":"8","author":"Picano","year":"1991","journal-title":"Echocardiography"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Failure Reviews"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101366_bib0036","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.euje.2005.09.002","article-title":"Dynamic left ventricular outflow tract obstruction in senile cardiac amyloidosis","volume":"7","author":"Mookadam","year":"2006","journal-title":"Eur J Echocardiogr"},{"issue":"12","key":"10.1016\/j.cpcardiol.2022.101366_bib0037","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.healun.2007.09.014","article-title":"Rapid progression of left ventricular wall thickness predicts mortality in cardiac light-chain amyloidosis","volume":"26","author":"Kristen","year":"2007","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101366_bib0038","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0002-9149(97)00400-1","article-title":"Right ventricular dilation in primary amyloidosis: an independent predictor of survival","volume":"80","author":"Patel","year":"1997","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101366_bib0039","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.amjms.2015.12.015","article-title":"Risk Factors and Prognostic Role of Left Atrial Enlargement in Patients with Cardiac Light-Chain Amyloidosis","volume":"351","author":"Zhao","year":"2016","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101366_bib0040","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/01.CIR.83.3.808","article-title":"Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis, A Doppler echocardiography study","volume":"83","author":"Klein","year":"1991","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101366_bib0041","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101366_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytz162","article-title":"A case report of cardiac amyloidosis presenting with chronic pericardial effusion and conduction block","volume":"3","author":"John","year":"2019","journal-title":"European Heart Journal - Case Reports"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101366_bib0043","first-page":"A18","article-title":"21\u2005Intracardiac thrombi in cardiac amyloidosis, a common finding","volume":"105","author":"Kotecha","year":"2019","journal-title":"Heart"},{"issue":"19","key":"10.1016\/j.cpcardiol.2022.101366_bib0044","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0045","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/13506120902879681","article-title":"Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis","volume":"16","author":"Porciani","year":"2009","journal-title":"Amyloid"},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101366_bib0046","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0002-8703(98)70127-9","article-title":"Contribution of magnetic resonance imaging in the differential diagnosis of cardiac amyloidosis and symmetric hypertrophic cardiomyopathy","volume":"136","author":"Fattori","year":"1998","journal-title":"Am Heart J"},{"issue":"10","key":"10.1016\/j.cpcardiol.2022.101366_bib0047","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jacc.2007.10.049","article-title":"Cardiovascular Magnetic Resonance in Clinically Suspected Cardiac Amyloidosis: Noninvasive Imaging Compared to Endomyocardial Biopsy","volume":"51","author":"Vogelsberg","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0048","first-page":"133","article-title":"CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis","volume":"7","author":"Dungu","year":"2014","journal-title":"JACC: Cardiovascular Imaging"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101366_bib0049","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic Resonance in Transthyretin Cardiac Amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.cpcardiol.2022.101366_bib0050","first-page":"1166.e1","article-title":"Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging","volume":"32","author":"Narotsky","year":"2016","journal-title":"Can J Cardiol"},{"issue":"25","key":"10.1016\/j.cpcardiol.2022.101366_bib0051","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1016\/j.jacc.2018.03.536","article-title":"Myocardial Edema and Prognosis in Amyloidosis","volume":"71","author":"Kotecha","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0052","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1161\/01.CIR.0000152819.97857.9D","article-title":"Cardiovascular Magnetic Resonance in Cardiac Amyloidosis","volume":"111","author":"Maceira","year":"2005","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0053","first-page":"195","article-title":"99mTc-Pyrophosphate Scintigraphy for Differentiating Light-Chain Cardiac Amyloidosis From the Transthyretin-Related Familial and Senile Cardiac Amyloidoses","volume":"6","author":"Bokhari","year":"2013","journal-title":"Circulation: Cardiovascular Imaging"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101366_bib0054","first-page":"1366","article-title":"Current Role of PET Imaging in Cardiac Amyloidosis","volume":"61","author":"Vuthaluru","year":"2020","journal-title":"Journal of Nuclear Medicine"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101366_bib0055","first-page":"414","article-title":"Diuretic Dose and NYHA Functional Class Are Independent Predictors of Mortality in Patients With Transthyretin Cardiac Amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC: CardioOncology"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101366_bib0056","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1378\/chest.124.3.969","article-title":"Persistent Pleural Effusions in Primary Systemic Amyloidosis: Etiology and Prognosis","volume":"124","author":"Berk","year":"2003","journal-title":"Chest"},{"issue":"13","key":"10.1016\/j.cpcardiol.2022.101366_bib0057","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/0002-9149(85)90995-6","article-title":"Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents","volume":"55","author":"Gertz","year":"1985","journal-title":"The American Journal of Cardiology"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101366_bib0058","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1161\/01.CIR.63.6.1285","article-title":"Digoxin sensitivity in amyloid cardiomyopathy","volume":"63","author":"Rubinow","year":"1981","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.cpcardiol.2022.101366_bib0059","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"27","key":"10.1016\/j.cpcardiol.2022.101366_bib0060","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"European heart journal"},{"issue":"13","key":"10.1016\/j.cpcardiol.2022.101366_bib0061","first-page":"e210","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0062","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","article-title":"The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement","volume":"91","author":"Dubrey","year":"1998","journal-title":"QJM: An International Journal of Medicine"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101366_bib0063","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1007\/s00380-015-0658-0","article-title":"Late gadolinium enhancement in cardiac amyloidosis: attributable both to interstitial amyloid deposition and subendocardial fibrosis caused by ischemia","volume":"31","author":"Hashimura","year":"2016","journal-title":"Heart Vessels"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101366_bib0064","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0065","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.254","article-title":"Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis","volume":"222","author":"Hamon","year":"2016","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.cpcardiol.2022.101366_bib0066","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1460-9592.2001.01228.x","article-title":"Holter monitoring in AL amyloidosis: prognostic implications","volume":"24","author":"Palladini","year":"2001","journal-title":"Pacing Clin Electrophysiol"},{"issue":"18","key":"10.1016\/j.cpcardiol.2022.101366_bib0067","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016038","article-title":"Survival Following Implantable Cardioverter-Defibrillator Implantation in Patients With Amyloid Cardiomyopathy","volume":"9","author":"Higgins","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0068","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/HCO.0b013e32835dd165","article-title":"Current state of cardiac amyloidosis","volume":"28","author":"Sharma","year":"2013","journal-title":"Current opinion in cardiology"},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101366_bib0069","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bjh.12191","article-title":"Light chain amyloidosis 2012: a new era","volume":"160","author":"Gatt","year":"2013","journal-title":"British journal of haematology"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1201\/9781420037494-24","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","author":"Dispenzieri","year":"2004","journal-title":"Amyloid and Amyloidosis"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0071","first-page":"155","article-title":"Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis","volume":"3","author":"Syed","year":"2010","journal-title":"JACC: cardiovascular imaging"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0072","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ijcard.2016.04.030","article-title":"Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings","volume":"214","author":"Sperry","year":"2016","journal-title":"Int J Cardiol"},{"issue":"18","key":"10.1016\/j.cpcardiol.2022.101366_bib0073","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","article-title":"A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis","volume":"36","author":"Sayed","year":"2015","journal-title":"European heart journal"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101366_bib0074","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0735-1097(97)00267-2","article-title":"Electrophysiologic abnormalities in AL (primary) amyloidosis with cardiac involvement","volume":"30","author":"Reisinger","year":"1997","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0075","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.hrthm.2015.09.016","article-title":"Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy","volume":"13","author":"Barbhaiya","year":"2016","journal-title":"Heart Rhythm"},{"issue":"8","key":"10.1016\/j.cpcardiol.2022.101366_bib0076","first-page":"e333","volume":"140","author":"Kusumoto","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101366_bib0077","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ajh.24919","article-title":"Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL)","volume":"93","author":"Tandon","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2022.101366_bib0078","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1182\/blood.V88.7.2801.bloodjournal8872801","article-title":"Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients","volume":"88","author":"Comenzo","year":"1996","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cpcardiol.2022.101366_bib0079","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.11413","article-title":"Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response","volume":"92","author":"Gertz","year":"2007","journal-title":"Haematologica"},{"issue":"28","key":"10.1016\/j.cpcardiol.2022.101366_bib0080","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1200\/JCO.20.01285","article-title":"Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"19","key":"10.1016\/j.cpcardiol.2022.101366_bib0081","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","article-title":"Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival","volume":"119","author":"Venner","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.cpcardiol.2022.101366_bib0082","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"issue":"36","key":"10.1016\/j.cpcardiol.2022.101366_bib0083","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"Journal of clinical oncology"},{"issue":"17","key":"10.1016\/j.cpcardiol.2022.101366_bib0084","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101366_bib0085","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.echo.2010.03.027","article-title":"Independent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study","volume":"23","author":"Bellavia","year":"2010","journal-title":"Journal of the American Society of Echocardiography"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101366_bib0086","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","article-title":"Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis","volume":"28","author":"Kastritis","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"10","key":"10.1016\/j.cpcardiol.2022.101366_bib0087","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.15252\/emmm.201505357","article-title":"A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis","volume":"7","author":"Marcoux","year":"2015","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0088","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.cpcardiol.2022.101366_bib0089","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1517\/14656566.2016.1145664","article-title":"TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies","volume":"17","author":"Adams","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"24","key":"10.1016\/j.cpcardiol.2022.101366_bib0090","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.cpcardiol.2022.101366_bib0091","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.cpcardiol.2022.101366_bib0092","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nchembio839","article-title":"RNAi therapeutics: a potential new class of pharmaceutical drugs","volume":"2","author":"Bumcrot","year":"2006","journal-title":"Nat Chem Biol"},{"issue":"5","key":"10.1016\/j.cpcardiol.2022.101366_bib0093","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/FJC.0000000000001004","article-title":"A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis","volume":"77","author":"Benbrahim","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101366_bib0094","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis: analysis of the APOLLO Study","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0095","unstructured":"HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03759379"},{"key":"10.1016\/j.cpcardiol.2022.101366_bib0096","unstructured":"HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04153149"},{"issue":"12","key":"10.1016\/j.cpcardiol.2022.101366_bib0097","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1177\/10600280211000351","article-title":"Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies","volume":"55","author":"Yadav","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.cpcardiol.2022.101366_bib0098","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis","volume":"79","author":"Gertz","year":"2005","journal-title":"American journal of hematology"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101366_bib0099","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.16059","article-title":"Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial","volume":"187","author":"Boyle","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.cpcardiol.2022.101366_bib0100","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/cam4.725","article-title":"Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis","volume":"5","author":"Lisenko","year":"2016","journal-title":"Cancer medicine"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101366_bib0101","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1111\/bjh.16282","article-title":"Daratumumab is effective in the relapsed or refractory systemic light-chain amyloidosis but associated with high infection burden in a frail real-life population","volume":"188","author":"Van de Wyngaert","year":"2020","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.cpcardiol.2022.101366_bib0102","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood.2019004369","article-title":"A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis","volume":"135","author":"Roussel","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101366_bib0103","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-011-1244-x","article-title":"Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide","volume":"91","author":"Palladini","year":"2012","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0104","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/qjmed\/91.2.141","article-title":"The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement","volume":"91","author":"Dubrey","year":"1998","journal-title":"Qjm"},{"issue":"9","key":"10.1016\/j.cpcardiol.2022.101366_bib0106","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.cardfail.2019.04.011","article-title":"Waitlist mortality of patients with amyloid cardiomyopathy who are listed for heart transplantation and implications for organ allocation","volume":"25","author":"Panhwar","year":"2019","journal-title":"Journal of cardiac failure"},{"issue":"11","key":"10.1016\/j.cpcardiol.2022.101366_bib0107","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.healun.2004.08.025","article-title":"Outcome of heart transplantation in patients with amyloid cardiomyopathy","volume":"24","author":"Kpodonu","year":"2005","journal-title":"The Journal of heart and lung transplantation"},{"issue":"15","key":"10.1016\/j.cpcardiol.2022.101366_bib0108","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","article-title":"Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0109","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5500\/wjt.v6.i2.380","article-title":"Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience","volume":"6","author":"Grogan","year":"2016","journal-title":"World journal of transplantation"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101366_bib0110","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.healun.2011.09.010","article-title":"Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies","volume":"31","author":"Varr","year":"2012","journal-title":"The Journal of heart and lung transplantation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0111","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.healun.2013.09.004","article-title":"Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis","volume":"33","author":"Gilstrap","year":"2014","journal-title":"The Journal of Heart and Lung Transplantation"},{"issue":"2","key":"10.1016\/j.cpcardiol.2022.101366_bib0112","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.cpcardiol.2022.101366_bib0113","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.cpcardiol.2022.101366_bib0114","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/tri.12549","article-title":"Combined heart-liver transplantation: a single-center experience","volume":"28","author":"Careddu","year":"2015","journal-title":"Transpl Int"},{"issue":"1","key":"10.1016\/j.cpcardiol.2022.101366_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2015.10.023","article-title":"The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update","volume":"35","author":"Mehra","year":"2016","journal-title":"The Journal of Heart and Lung Transplantation"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622002638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280622002638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:59:22Z","timestamp":1758938362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280622002638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":115,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0146280622002638"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101366","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Review of Cardiac Amyloidosis: Presentation, Diagnosis, and Treatment","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2022.101366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"101366"}}